"OVCAR-8人卵巢癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實驗室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個容器轉(zhuǎn)移到另一個容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

Sarcoma OSteogenic-2 Cells;背景說明：該細(xì)胞是FoghJ和TrempeG分離和鑒定的眾多人類腫瘤細(xì)胞系中的一種；該細(xì)胞來自一位１１歲的白人女性的骨肉瘤組織?；颊呓?jīng)過放療以及甲喋呤、阿霉素、長春新堿、環(huán)磷酰胺和aramycin-C等多種藥物治療。該細(xì)胞在免疫抑制小鼠中不致瘤，細(xì)胞表達(dá)表皮生長因子EGF受體、轉(zhuǎn)化生長因子β（１型和２型）受體。;傳代方法：１：２-１：４傳代；每周１-２次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：8305C_1細(xì)胞、MZ-CRC-1細(xì)胞、MC116細(xì)胞

HPAF2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EB-2細(xì)胞、NCI-H1373細(xì)胞、NCIH358細(xì)胞

LN229 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Hs 870.T細(xì)胞、H647ell細(xì)胞、Swiss3T3細(xì)胞

OVCAR-8人卵巢癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見相關(guān)文獻(xiàn)介紹

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

細(xì)胞培養(yǎng)應(yīng)用于分子生物學(xué)、細(xì)胞生物學(xué)、遺傳學(xué)、免疫學(xué)、腫瘤學(xué)及病毒學(xué)等領(lǐng)域，細(xì)胞培養(yǎng)是指將細(xì)胞從動物或植物體內(nèi)取出，然后在適宜的人工環(huán)境中生長的過程。細(xì)胞可以在培養(yǎng)前直接從組織中取出并通過酶或機(jī)械方法進(jìn)行解離，也可以來源于已建立的細(xì)胞系。傳代培養(yǎng)是指當(dāng)細(xì)胞生長至高密度時，將其分殖至新的培養(yǎng)瓶中，以維持其生長和增殖。貼壁細(xì)胞是指在培養(yǎng)基表面附著生長的細(xì)胞，懸浮細(xì)胞是指在培養(yǎng)基中懸浮生長的細(xì)胞，不依附于培養(yǎng)皿表面。半貼壁半懸浮細(xì)胞同時具備貼壁細(xì)胞和懸浮細(xì)胞的特點，通常在培養(yǎng)基中部分附著生長，部分懸浮于培養(yǎng)基上。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

OVCAR-8人卵巢癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

SKMES1 Cells;背景說明：源于一位６５歲患有肺鱗狀細(xì)胞癌的白人男性，自轉(zhuǎn)移性胸腔積液分離而來。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MG63細(xì)胞、NU-GC-4細(xì)胞、SW-982細(xì)胞

SCC-25 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：１０傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：ZR75-1細(xì)胞、HUT 28細(xì)胞、RPMI #1846細(xì)胞

CNE1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OE33細(xì)胞、KMS-11細(xì)胞、HEK-293細(xì)胞

Loucy Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：２-３天換液１次。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣　;相關(guān)產(chǎn)品有：Hep G2/C3A細(xì)胞、Mc Ardle 7777細(xì)胞、Hs294T細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞株(系)的使用，為醫(yī)學(xué)研究和測試工作帶來了大的方便。但細(xì)胞的傳代是有限制的，長期連續(xù)傳代的細(xì)胞，不僅消耗大量的人力和物力，而且細(xì)胞的生長與形態(tài)等會有一定退變或轉(zhuǎn)化，因而細(xì)胞失去原有的遺傳性，有時還會由于細(xì)胞污染而造成傳代中斷，種子丟失。因此，在實際工作中常需凍存一定數(shù)量的細(xì)胞，以備替換使用。細(xì)胞冷凍與復(fù)蘇是細(xì)胞培養(yǎng) 室的常規(guī)工作和通用技術(shù)。目前，細(xì)胞凍存Zui常用的技術(shù)是冷凍保存法，主要采用加適量保護(hù)劑的緩慢冷凍法凍存細(xì)胞。細(xì)胞在不加任何保護(hù)劑的情況下直接冷凍，細(xì)胞內(nèi)外的水分會很快形成冰晶，從而引起一系列不良反應(yīng)。如細(xì)胞脫水使局部電解質(zhì)濃度增GAO，pH值改變，部分蛋白質(zhì)由于上述原因而變性，引起細(xì)胞內(nèi)部空間結(jié)構(gòu)紊亂，溶酶體膜由此遭到損傷而釋放出溶酶體酶，使細(xì)胞內(nèi)結(jié)構(gòu)成分造成破壞，線粒體腫脹，功能丟失，并造成能量代謝障礙。胞膜上的類脂蛋白復(fù)合體也易破壞引起細(xì)胞膜通透性的改變，使細(xì)胞內(nèi)容物丟失。如果細(xì)胞內(nèi)冰晶形成較多，隨冷凍溫度的降低，冰晶體積膨脹造成細(xì)胞核DNA空間構(gòu)型發(fā)生不可逆的損傷，而致細(xì)胞死亡。因此，細(xì)胞冷凍技術(shù)的關(guān)鍵是盡可能地減少細(xì)胞內(nèi)水分，減少細(xì)胞內(nèi)冰晶的形成。采用甘油或二甲基亞砜作保護(hù)劑，這兩種物質(zhì)分子量小，溶解度大，易穿透細(xì)胞，可以使冰點下降，提GAO細(xì)胞膜對水的通透性，且對細(xì)胞無明顯毒性。慢速冷凍方法又可使細(xì)胞內(nèi)的水分滲出細(xì)胞外，減少胞內(nèi)形成冰結(jié)晶的機(jī)會，從而減少冰晶對細(xì)胞的損傷。

NCI-H1048 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代；;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：TE 85.T細(xì)胞、CMT 167細(xì)胞、RAG細(xì)胞

MFE-296 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PIG1細(xì)胞、H-747細(xì)胞、A375mel細(xì)胞

TYK-nu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SEG-1細(xì)胞、Mv 1 Lu (NBL-7)細(xì)胞、HTSMC細(xì)胞

C-643 Cells;背景說明：甲狀腺未分化癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AD293細(xì)胞、RA.1細(xì)胞、Granta519細(xì)胞

HuTu 80 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：５傳代，每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：BT483細(xì)胞、MPC-83細(xì)胞、Nakata-1細(xì)胞

I90 Cells;背景說明：W.W. Nichols及其同事從一位１６周女嬰的肺中取材，建立了人二倍體成纖維細(xì)胞株IMR-９０。分裂潛能，病毒感受性和其它性質(zhì)都得到了充分研究，因而這株細(xì)胞可以作為WI-３８或其它標(biāo)準(zhǔn)人肺細(xì)胞株的替代株。有報道稱這株細(xì)胞在表現(xiàn)出衰老前可倍增５８次。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MES 13細(xì)胞、SW1463細(xì)胞、INS-1細(xì)胞

NCI-ADR-RES Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Wayne State University-Head and Neck 13細(xì)胞、RPMI1846細(xì)胞、WEHI164細(xì)胞

FOX-NY Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A-875細(xì)胞、C8161細(xì)胞、MLO-Y4細(xì)胞

Panc 08.13 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：AZ 521細(xì)胞、HKF細(xì)胞、HSAS1細(xì)胞

HuH 6 Cells;背景說明：肝癌。據(jù)說產(chǎn)球蛋白和甲胎蛋白。;傳代方法：消化３-５分鐘。１：２。６-７天長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：UACC812細(xì)胞、OE19細(xì)胞、NCI-SNU-601細(xì)胞

PLA 802 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCF-7ADR細(xì)胞、Fukuoka University-Malignant mixed Mullerian Tumor-1細(xì)胞、MGH-UI細(xì)胞

SUDHL2 Cells;背景說明：彌漫性大細(xì)胞淋巴瘤；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L-M (TK-)細(xì)胞、SV-HUC細(xì)胞、NCTC929細(xì)胞

SK-UT-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１２傳代，２天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：TE-14細(xì)胞、3-LL細(xì)胞、HPAEpiC細(xì)胞

MGH-U3 (RN) Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P3X63Ag8細(xì)胞、MCF-10 Attached細(xì)胞、BV-173細(xì)胞

HOP-92 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L-WRN細(xì)胞、SCC25細(xì)胞、LA-N-6細(xì)胞

DoTc2 4510 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代，每周換液２—３次;生長特性：貼壁生長　;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：COLO201細(xì)胞、SACC-83細(xì)胞、T-47-D細(xì)胞

GTL16 Cells;背景說明：胃癌；肝轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1184細(xì)胞、H-1341細(xì)胞、MBVP細(xì)胞

50B11 clone D4W Cells(提供STR鑒定圖譜)

Abcam K-562 DGKA KO Cells(提供STR鑒定圖譜)

ANE58 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRK340 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XM110 Cells(提供STR鑒定圖譜)

Calu-1 W5S2 Cells(提供STR鑒定圖譜)

DA00617 Cells(提供STR鑒定圖譜)

DA05953 Cells(提供STR鑒定圖譜)

GM00337 Cells(提供STR鑒定圖譜)

MILE SVEN 1 Cells;背景說明：MS１是１９９４年建株的胰島內(nèi)皮細(xì)胞株。原代培養(yǎng)的胰島內(nèi)皮細(xì)胞用抗G４１８的溫度敏感型SV４０大T抗原(tsA-５８-３)轉(zhuǎn)染?？剐钥寺∮每寺…h(huán)分離，并篩選吸收dil-Ac-LDL的。這株細(xì)胞保留了內(nèi)皮細(xì)胞的許多特性，如吸收乙?；疞DL和表達(dá)八因子相關(guān)抗原及BEGF受體。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AN3 CA細(xì)胞、Ha Fe細(xì)胞、GM04154細(xì)胞

OVCAR-8人卵巢癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

RGM1 Cells;背景說明：胃黏膜；上皮細(xì)胞；自發(fā)永生；Wistar;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C1R細(xì)胞、HT-29細(xì)胞、SKMel-28細(xì)胞

293 EBNA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Calu 3細(xì)胞、SUM159細(xì)胞、B 95-8細(xì)胞

NRK49F Cells;背景說明：腎；成纖維細(xì)胞；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SN4741細(xì)胞、GM04678細(xì)胞、3T3-L1 ad細(xì)胞

H1341 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：圓形細(xì)胞;相關(guān)產(chǎn)品有：T47D:A細(xì)胞、TE354.T細(xì)胞、H-1666細(xì)胞

H19-7 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GM07404細(xì)胞、OCI AML2細(xì)胞、SCL-II細(xì)胞

294.35.2.6.3 Cells(提供STR鑒定圖譜)

SK-BR-3 Cells;背景說明：這株細(xì)胞源自胸水。沒有病毒顆粒。亞顯微結(jié)構(gòu)特征包括微絲和橋粒，肝糖原顆粒，大溶酶體，成束的細(xì)胞質(zhì)纖絲。SK-BR-３細(xì)胞株過表達(dá)HER２/c-erb-２基因產(chǎn)物。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KMS11細(xì)胞、CAMA-1細(xì)胞、OVCAR 432細(xì)胞

H-526 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長 ;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HMEC-1細(xì)胞、GM05384細(xì)胞、Mono-Mac-1細(xì)胞

SKMEL28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：星形的;相關(guān)產(chǎn)品有：Panc 05.04細(xì)胞、Pt K1細(xì)胞、PC3M-1E8細(xì)胞

BNL 1ME A.7R.1 Cells;背景說明：肝；上皮細(xì)胞；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC2218細(xì)胞、SW 1573細(xì)胞、COLO 684細(xì)胞

ME1 Cells;背景說明：急性髓系白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE9細(xì)胞、Tb 1 Lu (NBL-12)細(xì)胞、NCI-H2228細(xì)胞

Hs-343-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：FL83B細(xì)胞、RCK-8細(xì)胞、HCT FET細(xì)胞

OV1-P Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H740細(xì)胞、SK-ChA-1細(xì)胞、UPCI:SCC154細(xì)胞

H-2141 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長;形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：67NR細(xì)胞、TK10細(xì)胞、bEND.3細(xì)胞

GM28879 Cells(提供STR鑒定圖譜)

HAP1 PEX3 (-) 2 Cells(提供STR鑒定圖譜)

MSTO-211 Cells;背景說明：MSTO-２１１H細(xì)胞株是１９８５年從一位肺二相間皮瘤患者的胸水中建株的。這個病人接受過多種藥物聯(lián)合前期化療。MSTO-２１１H細(xì)胞具有高親和力的EGF結(jié)合位點，并表達(dá)神經(jīng)元特異性烯醇酶(NSE)及人絨毛膜促性腺激素(HCG)的α與β亞基。未檢測到左旋多巴胺脫羧酶(DDC)，邦巴辛與神經(jīng)tensin。細(xì)胞過表達(dá)c-myc原癌基因，并沒有觀察到基因重排或擴(kuò)增。V-src,v-abl,v-erbB,c-raf１,Ha-ras,Ki-ras,和N-ras的表達(dá)呈陽性。未檢測到N-m;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：HSC2細(xì)胞、TFK1細(xì)胞、SK.MEL.2細(xì)胞

TE-12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNBE細(xì)胞、U2-OS細(xì)胞、SuDHL 1細(xì)胞

FCCH1024 Cells;背景說明：該細(xì)胞源自一位１４歲患有T淋巴細(xì)胞白血病男性的外周血;傳代方法：保持細(xì)胞密度在３—９×１０５cells/ml之間，１：５—１：１０傳代，每周換液２—３次;生長特性：懸浮生長;形態(tài)特性：圓形，單個或呈片;相關(guān)產(chǎn)品有：751-NA細(xì)胞、KBM-7細(xì)胞、Emory University-3細(xì)胞

DHL6 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，３—４天換液１次;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：KASUMI6細(xì)胞、C22細(xì)胞、LM(TK-)細(xì)胞

A-20 Cells;背景說明：淋巴瘤；BALB/cAnN;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EFM192A細(xì)胞、NPA 87細(xì)胞、SN4741細(xì)胞

JVM3 Cells;背景說明：慢性髓白血病；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-SNU-761細(xì)胞、MDA-MB-231細(xì)胞、SH-SY5Y細(xì)胞

SW 1271 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J774 A1細(xì)胞、T-T細(xì)胞、COLO-699細(xì)胞

Asian Medical Center-Head and Neck cancer-8 Cells;背景說明：喉癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L 540細(xì)胞、RMC細(xì)胞、P3-X63-Ag8-653細(xì)胞

hsAQC2 Cells(提供STR鑒定圖譜)

KOLF2.1J SEZ6L2 28.6KBDEL DEL/DEL Cells(提供STR鑒定圖譜)

MOLP-3 Cells(提供STR鑒定圖譜)

NYSCF-050956-01-MR Cells(提供STR鑒定圖譜)

RG-328 Cells(提供STR鑒定圖譜)

Ubigene HCT 116 DUSP10 KO Cells(提供STR鑒定圖譜)

VUi015-A Cells(提供STR鑒定圖譜)

HAP1 USP16 (-) 5 Cells(提供STR鑒定圖譜)

B-3 Cells;背景說明：晶狀體；Ad１２-SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO-738細(xì)胞、Hs578Bst細(xì)胞、H-2452細(xì)胞

ASH-3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1703細(xì)胞、SW756細(xì)胞、NCI-H2342細(xì)胞

SV-HUC-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Neuro 2a細(xì)胞、NCI-UMC-11細(xì)胞、NCI-SNU-475細(xì)胞

H-2196 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；每周換液２次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HTori 3細(xì)胞、PANC3.27細(xì)胞、C1R細(xì)胞

C-4I Cells;背景說明：宮頸鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BMF細(xì)胞、YH-13細(xì)胞、Pa18C細(xì)胞

C-4I Cells;背景說明：宮頸鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BMF細(xì)胞、YH-13細(xì)胞、Pa18C細(xì)胞

EFM-192A Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H524細(xì)胞、Anip 973細(xì)胞、Mv1Lu細(xì)胞

HS852.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HEL-299細(xì)胞、NCIH1915細(xì)胞、Fetal Rhesus Kidney-4細(xì)胞

NCIH1573 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CT26細(xì)胞、KYSE50細(xì)胞、MOVAS細(xì)胞

U-266 AR1 Cells;背景說明：骨髓瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DI TNC1細(xì)胞、SU86.86細(xì)胞、H1819細(xì)胞

C42 Cells;背景說明：前列腺癌；左鎖骨上淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LUDLU-1細(xì)胞、1E8-H細(xì)胞、PLA 802細(xì)胞

C57/B6-L Cells;背景說明：肺；成纖維細(xì)胞；C５７;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs611T細(xì)胞、CCD-112CoN細(xì)胞、P3 88 D1細(xì)胞

SCC154 Cells;背景說明：舌鱗癌；男性；HPV６轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Plaepi 34細(xì)胞、VM-CUB1細(xì)胞、BHT101細(xì)胞

PANC0327 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：3T3 L1細(xì)胞、EU-2細(xì)胞、Granta-519細(xì)胞

C3H10T1/2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH1573細(xì)胞、PCI-04B細(xì)胞、HCEpiC細(xì)胞

STSAR-104 Cells(提供STR鑒定圖譜)

H1299 Cells;背景說明：這株細(xì)胞來源于一個淋巴結(jié)轉(zhuǎn)移。患者接受了初期放療。細(xì)胞均一性的部分缺失p５３蛋白，并缺少p５３蛋白表達(dá)。細(xì)胞可以合成０.１pmol/毫克蛋白的NMB蛋白，而不合成促胃液釋放肽(GRP)。;傳代方法：１：２傳代；３天傳代一次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：C-4-I細(xì)胞、Jurkat細(xì)胞、T8細(xì)胞

NCI-H157 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Tu 212細(xì)胞、SUD4細(xì)胞、CAL 12T細(xì)胞

SK-ChA-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CHL細(xì)胞、PC-3細(xì)胞、TOV-112D細(xì)胞

EFM-192C Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C-33A細(xì)胞、MDAPC2B細(xì)胞、293-H細(xì)胞

COS7 Cells;背景說明：此細(xì)胞株源自CV-１細(xì)胞株，經(jīng)轉(zhuǎn)染起始點缺失的SV４０病毒突變體得到；編碼表達(dá)野生型T抗原，所以該細(xì)胞適合作為需要SV４０T抗原表達(dá)的載體的轉(zhuǎn)染宿主。該細(xì)胞表達(dá)T抗原，允許SV４０病毒的溶解性生長，支持４０℃時溫度敏感性A２０９病毒的復(fù)制，支持起始區(qū)域缺陷的SV４０突變體的復(fù)制。因含有SV４０病毒的DNA序列，該細(xì)胞需要在２級生物安全柜中操作。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：BALB/3T3 cl. A31細(xì)胞、HR1K細(xì)胞、Vx2細(xì)胞

NCTC-3960 Cells;背景說明：黑色素瘤；雄性；DBA;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：JVM-2細(xì)胞、HuT102細(xì)胞、TPC-1細(xì)胞

OVCAR-8人卵巢癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

OCI-Ly7 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NRK 49F細(xì)胞、HFT 8810細(xì)胞、PC-2 [Human pancreatic carcinoma]細(xì)胞

SKNBE Cells;背景說明：１９７２年１１月從一們多次化療及放療的擴(kuò)散性神經(jīng)母細(xì)胞瘤患兒骨髓穿刺物中建立了SK-N-BE(２)神經(jīng)母細(xì)胞瘤細(xì)胞株。 該細(xì)胞顯示中等水平的多巴胺-β-羥基酶活性。 有報道稱SK-N-BE(２)細(xì)胞的飽和濃度超過１x１０６細(xì)胞/平方厘米。細(xì)胞形態(tài)多樣，有的有長突觸，有的呈上皮細(xì)胞樣。 細(xì)胞會聚集，形成團(tuán)塊并浮起;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：PZ-HPV-7細(xì)胞、L-132細(xì)胞、H-446細(xì)胞

K299 Cells;背景說明：間變性大細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CL34細(xì)胞、H-2347細(xì)胞、NK-92細(xì)胞

Highly Aggressively Proliferating Immortalized Cells;背景說明：小膠質(zhì)細(xì)胞；自發(fā)永生；Wistar;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：半貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：THP 1細(xì)胞、Anip[973]細(xì)胞、H2110細(xì)胞

P3-X63-Ag8.653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IMR 32細(xì)胞、MEG01細(xì)胞、C38細(xì)胞

EFM192 Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUDHL8細(xì)胞、HME-1細(xì)胞、SCL-I細(xì)胞

H-2122 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：B16-F1細(xì)胞、ACHN細(xì)胞、293FT細(xì)胞

H2227 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：該細(xì)胞既有懸浮生長，又有貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Hs 281.T細(xì)胞、ATN1細(xì)胞、2T細(xì)胞

BayGenomics ES cell line HMA249 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB470 Cells(提供STR鑒定圖譜)

CJ.F4 Cells(提供STR鑒定圖譜)

MANDYS13-6G1 Cells(提供STR鑒定圖譜)

rSN-21-2 Cells(提供STR鑒定圖譜)

UMR-105 Cells(提供STR鑒定圖譜)

" "PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805

Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C., Anderson M.E.

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992)

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

PubMed=9041185

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Cancer Res. 57:850-856(1997)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887

Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758

Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T.J., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.

Gene expression patterns in ovarian carcinomas.

Mol. Biol. Cell 14:4376-4386(2003)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445

Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Oncol. Rep. 23:1021-1026(2010)

DOI=10.4172/2157-7145.S2-005

Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.

STR profiling of human cell lines: challenges and possible solutions to the growing problem.

J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z

Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Invest. New Drugs 30:2035-2045(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677

Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023

Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mol. Oncol. 7:567-579(2013)

PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Evaluating cell lines as tumour models by comparison of genomic profiles.

Nat. Commun. 4:2126.1-2126.10(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837

Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

Type-specific cell line models for type-specific ovarian cancer research.

PLoS ONE 8:E72162-E72162(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516

Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Gynecol. Oncol. 142:332-340(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028

Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945

Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"